Welcome to our dedicated page for NeuroSense Therapeutics Ltd. SEC filings (Ticker: NRSNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to present SEC-related information for NeuroSense Therapeutics Ltd. in connection with the NRSNW symbol. NeuroSense is a clinical-stage biotechnology company that describes its focus as discovering and developing treatments for debilitating neurodegenerative diseases, including ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead candidate, PrimeC, is a novel extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, designed to target multiple mechanisms involved in ALS and Alzheimer's disease.
While no specific SEC filings are listed in the available data for this symbol, investors commonly look to regulatory documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K to better understand a company’s business description, risk factors and program updates. For a company like NeuroSense, such filings can provide additional detail on its clinical-stage pipeline, including PrimeC, and on its strategy to develop combined therapies targeting multiple pathways associated with neurodegenerative diseases.
On Stock Titan, the SEC filings page is designed to surface these documents as they become available from EDGAR, along with AI-powered summaries that explain key sections in clearer language. When filings are present, users can review disclosures on topics such as clinical development progress, research activities and other company updates, and can also access insider transaction reports on Form 4 when applicable.
As filings for NRSNW are recorded, this page will help organize them by form type and date, and AI-generated insights will highlight important points so readers can more quickly understand how NeuroSense describes its business, programs and associated risks in its official SEC documents.
NeuroSense Therapeutics plans to file a New Drug Submission with Health Canada for its lead candidate PrimeC to treat amyotrophic lateral sclerosis, following a constructive Pre-New Drug Submission meeting in which regulators reviewed updated Phase 2b data.
The company presented achievement of the trial’s prespecified primary TDP-43 biomarker endpoint (p=0.0421) and long-term survival results, including a 14.9-month median survival benefit with PrimeC (hazard ratio 0.35, p=0.0037), alongside external natural history analyses and mechanistic and translational data. NeuroSense describes this regulatory interaction as an important milestone and intends to continue working with Health Canada while preparing the filing. PrimeC is an oral fixed-dose combination of ciprofloxacin and celecoxib, and the FDA has cleared a pivotal Phase 3 ALS trial (PARAGON) expected to enroll approximately 300 participants.
NeuroSense Therapeutics reported that its Phase 2b trial of PrimeC in amyotrophic lateral sclerosis (ALS) met its primary efficacy endpoint. PrimeC produced a statistically significant reduction in TDP-43, a core pathological hallmark present in more than 97% of ALS cases, versus placebo at Day 180 (p=0.0421).
The reduction in neuron‑derived TDP-43, measured using NeuroDex’s ExoSORT platform, deepened and remained statistically significant through 18 months (Day 540, p<0.001). Company and academic experts state that these biomarker results align with previously reported slowing of disease progression, survival benefit, and consistent biomarker data from the same study.
NeuroSense has FDA clearance to initiate its pivotal Phase 3 PARAGON trial in ALS, which is expected to enroll about 300 participants, primarily in the United States, advancing PrimeC as a potential disease‑modifying oral therapy targeting multiple ALS pathways.
NeuroSense Therapeutics furnished a Form 6-K highlighting early clinical data from its Phase 2 RoAD proof-of-concept study of PrimeC in Alzheimer’s disease. The eight-patient trial generated biomarker data from three participants who completed 12 months of follow-up with plasma and CSF sampling.
Analyses showed distinctive changes in hallmark Alzheimer’s biomarkers, including brain-derived tau (total), phospho-tau proteins, and the amyloid-beta 42/40 ratio. Additional changes appeared in misfolded proteins linked to other neurodegenerative diseases, such as alpha-synuclein and TDP-43, as well as markers of oxidative stress and inflammation. These shifts were directionally consistent with PrimeC’s proposed multi-target mechanism and with biomarker effects previously observed in the company’s ALS program, while maintaining a favorable safety and tolerability profile with no serious adverse events reported in RoAD.
NeuroSense Therapeutics Ltd. Chief Executive Officer Ben-Noon Alon acquired 250,000 ordinary shares on June 16, 2026 at $0.80 per share. The purchase was made in a private placement under a Securities Purchase Agreement dated April 28, 2026, exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Following this transaction, Alon directly holds 4,534,233 ordinary shares.
NeuroSense Therapeutics Ltd. Chief Financial Officer Or Eisenberg reported an open-market-style purchase of the company’s ordinary shares. On June 16, 2026, he acquired 250,000 ordinary shares at a price of $0.80 per share under a Securities Purchase Agreement dated April 28, 2026, executed as a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Following this transaction, his direct holdings increased to 1,504,050 ordinary shares.
NeuroSense Therapeutics reported that the Korean Intellectual Property Office granted Korean Patent Number 10-2969898 covering the composition of PrimeC, its lead drug candidate for amyotrophic lateral sclerosis (ALS). The patent covers PrimeC’s proprietary tablet formulation, manufacturing process, pharmacokinetic profile, and its use in treating ALS, and is expected to protect these aspects in South Korea through 2042.
The company describes this as strengthening its global intellectual property around PrimeC and aligning with its plan to advance into a pivotal Phase 3 PARAGON trial in ALS, for which it has already received U.S. FDA clearance. PrimeC is a novel oral combination of ciprofloxacin and celecoxib designed to target multiple ALS-related disease mechanisms, and earlier Phase 2b data showed slowing of disease progression, biomarker activity, and a reported survival benefit.
NeuroSense Therapeutics reports that the Japan Patent Office has granted Japanese Patent 7857044 covering its lead ALS drug candidate, PrimeC. The patent includes 17 claims and protects PrimeC’s unique extended-release composition and manufacturing process through 2042, including its synchronized delivery of ciprofloxacin and celecoxib.
The company describes this patent as a key part of its global intellectual property portfolio and long-term commercialization strategy in Japan. PrimeC has shown clinical, biomarker, and survival benefits in a Phase 2b ALS study, and NeuroSense has FDA clearance to initiate the pivotal Phase 3 PARAGON trial, expected to enroll about 300 participants.
NeuroSense Therapeutics reports a regulatory milestone for its ALS drug candidate PrimeC. The company recently held a constructive meeting with Health Canada to discuss potential regulatory pathways supporting a New Drug Submission (NDS) for treating amyotrophic lateral sclerosis.
NeuroSense presented additional clinical, biomarker, and long-term outcome data as previously requested by Health Canada, and outlined its proposed NDS strategy. The company expects an official response from Health Canada in the third quarter this year and plans to provide further updates on the Canadian regulatory process.
NeuroSense Therapeutics Ltd. entered a definitive agreement for an insider-led PIPE private placement of $600,000 in ordinary shares. The company will sell 750,000 shares at $0.80 each, a price 6.7% above the April 27, 2026 closing share price.
CEO Alon Ben-Noon, CFO Or Eisenberg, and a significant existing shareholder each committed $200,000. The financing is expected to close during the week of May 3, 2026, subject to customary conditions. NeuroSense plans to use the proceeds for general corporate purposes ahead of upcoming clinical and regulatory milestones.
NeuroSense Therapeutics Ltd. reported a leadership change in its medical team. Dr. Ferenc Tracik will step down as Chief Medical Officer effective April 27, 2026, but will remain involved with the company as an independent advisor.
The company states that his departure does not arise from any disagreement on operations, policies, or practices. In his advisory role, Dr. Tracik will continue to support clinical development and provide strategic medical guidance for the PrimeC program, including around an upcoming Pre-NDS meeting with Health Canada.